Shionogi's Xocova Now Available in U.S. for COVID-19 Post-Exposure Prevention

AI-generated NewsSnap summary based on source reporting.
Published: 2026-07-29
Category: health
Source: Shionogi (via PR Newswire)
Original source

Shionogi has announced the U.S. availability of Xocova (ensitrelvir), an oral antiviral for COVID-19 post-exposure prevention. This marks the first and only oral option for preventing COVID-19 after exposure, based on positive results from the SCORPIO-PEP trial. It offers a new tool in managing the spread of the virus.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai